Talaporfin

Drug Profile

Talaporfin

Alternative Names: Aptocine; Laserphyrin; Leserfin; Litx; LS 11; ME 2906; Mono-L-aspartyl chlorin e6; MR 901; NP e6; NPE 6; Talaporfin sodium; Taporfin sodium

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Light Sciences Oncology; Meiji Seika Pharma; The Childrens Hospital of Philadelphia
  • Class Antineoplastics; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glioma; Lung cancer; Oesophageal cancer
  • Phase II Benign prostatic hyperplasia
  • No development reported Cardiovascular disorders; Colorectal cancer; Hepatocellular carcinoma; Prostate cancer
  • Discontinued Age-related macular degeneration; Neurofibromatoses

Most Recent Events

  • 10 Jul 2017 Phase-II development for Benign prostatic hyperplasia is ongoing in USA (IV) (Light Sciences Oncology website, July 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 06 May 2015 No recent reports on development identified - Phase-I/II for Hepatocellular carcinoma in Taiwan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top